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Abstract
The aim of this study was to investigate the expression of prostaglandin EP1 receptor within the ventrolateral
periaqueductal grey (VL PAG). The role of VL PAG EP1 receptor in controlling thermonociception and rostral
ventromedial medulla (RVM) activity in healthy and neuropathic rats was also examined. EP1 receptor was indeed
found to be expressed within the VL PAG and co-localized with vesicular GABA transporter. Intra-VL PAG
microinjection of ONO-DI-004, a selective EP1 receptor agonist, dose-dependently reduced tail flick latency as well
as respectively increasing and decreasing the spontaneous activity of ON and OFF cells. Furthermore, it increased
the ON cell burst and OFF cell pause. Intra-VL PAG prostaglandin E2 (PGE2) behaved similarly to ONO-DI-004. The
effects of ONO-DI-004 and PGE2 were antagonized by intra-VL PAG L335677, a selective EP1 receptor antagonist.
L335677 dose-dependently increased the tail flick latency and ongoing activity of the OFF cells, while reducing the
ongoing ON cell activity. It also decreased the ON cell burst and OFF cell pause. In neuropathic rats using spare
nerve injury (SNI) of the sciatic nerve model, EP1 receptor expression decreased in the VL PAG. However, ONO-DI-
004 and L335677 were able to alter pain responses and ON and OFF cell activity, as they did in healthy animals.
Collectively, these data show that within the VL PAG, EP1 receptor has a facilitatory effect on the nociceptive
response and consistently affects RVM neuron activity. Thus, the blockade of EP1 receptor in the VL PAG leads to
antinociception in neuropathic pain conditions, despite its down-regulation. The expression of EP1 receptor on
GABAergic neurons is consistent with an EP1 receptor blockade-induced disinhibition of the antinociceptive
descending pathway at VL PAG level.
Keywords: EP1 receptor, tail flick, ON and OFF cell activity, antinociceptive descending pathway, spared nerve
injury, rat.
Background
It has been well established that prostaglandin E2
(PGE2) sensitizes peripheral nociceptors through the
activation of prostaglandin EP receptors present on the
peripheral terminals of sensory neurons, leading to a
r e d u c t i o ni np a i nt h r e s h o l da n di n c r e a s e dr e s p o n s i v e -
ness [1]. As well as a peripheral role, spinal prostaglan-
dins (PGs) contribute to dorsal horn sensitization in
persistent pain states in the spinal cord [2,3].
Nevertheless, little attention has been given to PG action
at supraspinal level and in particular within the antino-
ciceptive descending pathway, consisting of periaque-
ductal grey (PAG), rostral ventromedial medulla (RVM)
and spinal dorsal horn components. PAG-induced con-
trol of nociception is produced concomitantly with the
modulation of neuron activity within the RVM: ON-
cells, which are activated and OFF-cells, which are
inhibited by cutaneous nociceptive stimuli [4]. Unlike
ON and OFF cells, another class of neurons; the neutral
cells, are instead unaffected by noxious stimuli. * Correspondence: sabatino.maione@unina2.it
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COX-2, PGE2 and the prostaglandin EP3 receptor have
been identified within the PAG [5-7]. Intra-PAG micro-
injection of a COX1-2 inhibitor, lysine-acetylsalcylate,
reduced nociceptive processing [8,9]. The involvement
of PAG PGs in tonic facilitatory control on spinal noci-
ception [10] and that of PGE2 in the genesis of hyperal-
gesia and spontaneous pain at spinal dorsal horn level
[11] has already been recognized. On this subject, EP
receptor subtype antagonist may potentially behave like
an analgesic at this level. Indeed, in one of our previous
studies, we demonstrated that intra-PAG microinjec-
tions of EP1-4 receptor subtype antagonists prevented
formalin and misoprostol-induced hyperalgesia in mice,
demonstrating a key role of PGs in a facilitating noci-
ceptive response throughout EP receptors at PAG level
[12]. As far as chronic pain is concerned, insights into
the role of EP1 receptor are still scant, although it has
been reported that selective pharmacological blockade of
EP1 receptor or its gene ablation counteracts pain in
animal models of neuropathic pain [13-17]. Stimulation
of EP1 receptor leads to a [Ca
2+] increase and neuro-
transmitter release [3,18], and its pharmacological
manipulation within the descending pathway of pain
could therefore be a suitable strategy for pain relief.
Since there is no evidence to date of EP1 receptor
expression in the VL PAG, in this study we investigated
the presence of EP1 receptor within the VL-PAG, its
possible contribution to thermonociception and to the
modulation of the ongoing and tail flick-related activity
of RVM ON and OFF cells in physiological and neuro-
pathic pain conditions.
Methods
Animals
Male Wistar rats (220-250 g) were housed under con-
trolled conditions (12 h light/12 h dark cycle; tempera-
ture 20-22°C; humidity 55-60%) with chow and tap
water available ad libitum. All surgery and experimental
procedures were performed during the light cycle and
were approved by the Animal Ethics Committee of The
Second University of Naples. Animal care was in com-
pliance with Italian (D.L. 116/92) and EC (O.J. of E.C.
L358/1 18/12/86) regulations on the protection of
laboratory animals. All efforts were made to reduce both
animal numbers and suffering during the experiments.
The spared nerve injury model
The spared nerve injury model of neuropathic pain was
induced according to the method used by Decosterd
and Woolf [19]. Rats were anaesthetised with sodium
pentobarbital (50 mg/kg, i.p.). The sciatic nerve was
exposed at the level of its trifurcation into sural, tibial
and common peroneal nerves. The sural and common
peroneal nerves were ligated tightly then transected just
distal to the ligation, leaving the tibial nerve intact.
Sham rats were anaesthetised, the sciatic nerve was
exposed at the same level, but not ligated. Seven days
after surgery sham and SNI rats underwent tail flick
tests coupled with single unit extracellular recording
experiments or were sacrificed for immunohistochemis-
try, RT-PCR and western blot analysis.
Immunohistochemistry
Healthy, sham and SNI rats where anaesthetized with
pentobarbital (50 mg/kg, i.p.) and transcardially perfused
with saline solution followed by 4% paraformaldehyde in
0.1 M phosphate buffer. The brain was removed, post
fixed for 4 hours in the perfusion fixative, cryoprotected
for 72 hours in 30% sucrose in 0.1 M phosphate buffer
and frozen in O.C.T. embedding compound. Transverse
sections (15 μm) were cut using a cryostat and those
containing the whole PAG were thaw-mounted onto
glass slides. Sections were subsequently incubated for 1
day at room temperature in a humid chamber with the
respective polyclonal antibodies (all diluted in block
solution). All sections were processed for rabbit anti-
vesicular glutamate transporter-1 (VGluT1) (1: 500,
SySy, Germany), rabbit anti-vesicular GABA transporter
(VGAT) (1:250, SySy, Germany) and goat-anti EP1
receptor (1:100, Santa Cruz, USA).
Following incubation, sections were washed and incu-
bated for 3 hours with secondary antibody solution
(goat anti-rabbit, or donkey anti-goat, IgG-conjugated
Alexa FluorTM 488 and 568; 1:1000; Molecular Probes,
USA). Slides were washed, cover-slipped with Vecta-
shield mounting medium (Vector Laboratories, USA)
and visualized under a Leica fluorescence microscope.
Quantitative analysis of EP1/VGluT1 and EP1/VGAT
co-localization was performed within the ventrolateral
sub region of the PAG (Figure 1A) by an observer blind
to the experiment. Only the stained cells counterstained
with DAPI were counted as positive profiles. Negative
control by using secondary antibodies alone did not
reveal any positive staining.
Western blotting
A block of tissue containing the PAG was cut using a
vibrotome (Vibratome 1500, Warner Instruments, Ham-
den, CT, USA). A brainstem slice of 1.5 mm was cut
throughout the rostral part of the PAG (interaural from
+1.7 mm to +0.2 mm) [20]and the VL sub region was
then isolated under optical microscope (M650, Wild
Heerbrugg, Switzerland). VL PAG was first minced into
small pieces with a blender, and then incubated over-
night at 4°C with goat polyclonal anti-EP1 antibody
(1:200 dilution; sc-22648, Santa Cruz, CA, USA); reac-
tive bands were detected by chemiluminescence
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station (BioRad). Thirty micrograms of protein derived
from 6 pooled VL PAG tissues were loaded for each
sample. An anti-beta-actin (1:5000; Sigma, Milan, Italy)
was used to check for identical protein loading. Images
were captured using a ChemiDoc XRS system (Biorad),
stored, and analyzed with the Quantity One software
(BioRad). The quantified values were normalized to
beta-actin, which was chosen as housekeeping protein.
Surgical preparation for single unit electrophysiological
recordings coupled with tail flick
For electrophysiological experiments combined with the
tail flick test, rats were anaesthetised with pentobarbital
(50 mg/kg, i.p.) and a 26-gauge, 12 mm long stainless
steel guide cannula was stereotaxically lowered until its
t i pw a s1 . 5m ma b o v et h el e f tV LP A Gb ya p p l y i n g
coordinates (A: -7.8 mm from bregma, L: 0.5 mm, V:
4.5 mm below the dura) from the Atlas of Paxinos and
Watson [20]. The cannula was anchored with dental
cement to a stainless steel screw in the skull. David
Kopf stereotaxic apparatus was used (David Kopf Instru-
ments, Tujunga, CA, USA) with the animal positioned
on a homeothermic temperature control blanket (Har-
vard Apparatus Limited, Edenbridge, Kent) set at 37°C.
S u r g e r yf o rc a n n u l ai m p l a n t ation was carried out the
same day as the electrophysiology coupled with tail flick
experiments.
Intra-VL PAG microinjections
Direct intra-VL PAG administration of drugs, or respec-
tive vehicle, was conducted with a stainless steel cannula
connected to a SGE 1-microlitre syringe via a polyethy-
lene tube, inserted through the guide cannula and
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Figure 1 A shows a high magnification microscopy microphotography of VL PAG. B and B’ show the western blot analysis and relative
quantification of EP1 receptor protein levels within the VL PAG in sham and SNI rats. C shows the double staining quantification for GABA
vesicular transporter (VGAT) and glutamate vesicular transporter (VGluT) with EP1 receptor. The merge in C’ indicates the co-localization of EP1
(red) and VGAT (green) labelled profiles. The arrow in the upper panel represents a positive EP1 profile which is not counterstained with VGAT,
while the asterisks represent the double positive labelling EP1/VGAT. The lower panel shows the double staining for vesicular glutamate
transporter VGluT1 (green) and EP1 receptor (red). The merge indicates the extremely scarce presence of EP1 in the VGluT1 labelled
glutamatergic neuron, as highlighted by the arrows. Data represent mean ± S.E.M., n=6rats per group. Scale bars = 50 μm.
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Vehicle or drug solutions were administered into the VL
PAG in a final volume of 200 nl. Microinjection was
performed over a period of 60 sec and the injection can-
nula gently removed 2 min later. At the end of the
experiment, a volume of 200 nl of neutral red (0.1%)
was also injected into the VL PAG 30-40 min prior to
killing the rat. Rats were then perfused intracardially
with 20 ml phosphate buffer solution (PBS) followed by
200 ml 10% formalin solution in PBS. The brains were
removed and immersed in a saturated formalin solution
for 2 days. The injection sites were ascertained by using
2 consecutive sections (40 μm), one stained with neutral
red to identify nuclei and the other unstained in order
to determine dye spreading.
RVM extracellular recordings
After implantation of the guide cannula into the VL PAG, a
glass insulated tungsten filament electrode (3-5 MΩ)( F r e -
derick Haer & Co., ME, USA) was stereotaxically lowered
through a small craniotomy into the RVM (2.8-3.3 mm
caudal to lambda, 0.4-0.9 mm lateral and 8.9-10.7 mm
depth from the surface of the brain), using the coordinates
from the atlas of Paxinos and Watson [20]. The jugular
vein was cannulated so as to facilitate the intravenous
administration of the anaesthetic (propofol, 8-10 mg/kg/h,
i.v.). Anaesthesia was adjusted so that tail flicks were eli-
cited with a constant latency < 6 sec. The level of anaesthe-
sia was considered stable if animals maintained a constant
tail flick latency lasting 30-40 min before recording. We did
not observe any overt changes in latency in reaching anaes-
thetic stability in SNI, sham and healthy rats, although SNI
rats showed a lower tail flick latency than controls. The
thermal stimulus was elicited by a radiant heat source of a
tail flick unit (Ugo Basile, Varese, Italy) focused on the rat’s
tail approximately 4-5 cm from its tip. The tail was placed
over the surface of a slightly projecting window receiving
the I.R. energy. The I.R. intensity of the tail flick unit in our
experiments was set to 50 mW corresponding to 50 mJ per
sec. Tail flick latency in seconds was determined by a timer
connected to a photoelectric cell which stopped the timer
(and switched off the lamp) whenever the the tail was with-
drawn. Tail flicks were elicited every 5 min for at least 15
min prior to microinjecting drugs, or the respective vehicle,
0.05% dimethyl sulfoxide (DMSO) in artificial cerebrospinal
fluid (ACSF, composition in mM: KCl 2.5; NaCl 125;
MgCl2 1.18; CaCl2 1.26) into the VL PAG. Spike waveforms
were displayed on an oscilloscope in order to ensure that
the unit under study was unambiguously discriminated
throughout the experiment. Signals were also processed
using an interface (CED 1401) (Cambridge Electronic
Design Ltd., UK) connected to a Pentium III PC. Spike2
software (CED, version 4) was used to create peristimulus
rate histograms on-line and to store and analyse digital
records of single-unit activity off-line. Configuration, shape,
and height of the recorded action potentials were moni-
tored and recorded continuously using a window discrimi-
nator and Spike2 software for on-line and off-line analysis.
Once background cellular activity was detected during cell
search within the RVM, ON and OFF cells were identified
by the tail flick stimulus. ON cells were identified by a
burst of activity beginning immediately prior to a nocifen-
sor reflex to the tail flick, while OFF cells were identified by
the fact that they ceased firing at that time [21]. Three or
more thermal noxious stimulus trials were applied through
the tail flick unit to the tail at intervals of 5 min in order to
characterize RVM cells. A trial was not initiated if an ON
or OFF cell showed constant background activity for at
least 10 s. Once an RVM cell had been identified as ON,
OFF or neutral, we optimised spike size before any treat-
ment. This study only included neurons whose spike con-
figuration remained constant and could clearly be
discriminated from activity in the background throughout
the experiment, indicating that the activity from a single
neuron was measured. However this study did not include
recordings of the neutral cells that were encountered dur-
ing the cell search (n = 24 in healthy, n = 8 in sham and n
= 8 in SNI rats, corresponding to 16.2, 15.8 and 14.26% of
the cells encountered in healthy, sham and SNI groups,
respectively). The recording site was marked with a 20 μA
DC current for 20 s. After fixation by immersion in 10%
formalin, the recording sites were identified. In each rat,
only one neuron was recorded before and after vehicle or
drug administration. Neuron responses both before and
after intra-VL PAG vehicle or drug microinjections were
measured and expressed as spikes/sec (Hz). At the end of
the experiment, each animal was killed with a lethal dose of
urethane, the microinjection site was marked with 0.2 μlo f
a Cresyl Violet solution and the recording site marked with
a2 0μA DC current for 20 s. After fixation by immersion
in 10% formalin, the microinjection and recording sites
were identified.
Treatments
Healthy animals receiving a single intra-VL PAG admin-
istration of 200 nl vehicle (DMSO/ACSF, 0.05%, v/v),
ONO-DI-004 (Ki = 0.15 μMa n dE C 50 =0 . 4 2μMa t
EP1 receptor, [22]), PGE2 or L335677 (Ki = 15 nM with
a selectivity of at least 100-fold against EP2, EP4, FP
and IP and 67-, 11-, and 10-fold against EP3, DP and
TP receptors, respectively [23]) were grouped as follows:
a) Group 1 rats receiving vehicle;
b) Group 2 rats receiving different doses of ONO-DI-
004 (0.001, 0.01 and 0.1 pg), a selective EP1 receptor
agonist;
c) Group 3 rats receiving 0.1 pg of ONO- DI-004 in
combination with L-335677 (0.1 pg), a selective EP1
receptor antagonist;
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(0.01, 0.1 and 1 pg);
e) Group 5 rats receiving 1 pg of PGE2 in combina-
tion with L-335677 (0.1 pg);
f) Group 6 rats receiving different doses of L-335677
(0. 1, 1 and 10 pg);
g) Group 7 rats receiving ONO-DI-004 (0.1 pg) inten-
tionally outside the VL PAG.
Sham and SNI animals receiving a single intra-VL
PAG administration of 200 nl vehicle (DMSO/ACSF,
0.05%, v/v) or drug solutions 7 days after surgery were
grouped as follows:
1) Sham and SNI rats receiving vehicle;
2) Sham and SNI rats receiving ONO-DI-004 (0.1 pg);
3) Sham and SNI rats receiving L-335677 (10 pg).
Since only one neuron was recorded in each rat,
experimental groups consisted of 12-14 rats in order to
record at least 6-7 ON and 6-7 OFF cells for each treat-
ment. Only group g consisted of 7 rats which were used
for monitoring tail flick latency only, in order to verify
the specificity of the effect of the microinjection site.
When L-335677 was used in combination with ONO-
DI-004 or PGE2, the latters were administered 10 min-
utes after L-335677.
Statistics
B e h a v i o u r a ld a t aw e r ee x p r e s s e da sm e a n s±S . E . Mo f
latency time to the tail withdrawal reflex. RVM back-
ground cell activity was expressed as means ± SEM of
the spikes/s obtained by averaging the ongoing cell fir-
ing recorded in the 50 s prior to tail flick trials (which
were carried out every 5 min). ON cells identified by a
burst of activity just before tail flick responses were
spontaneously active in 31.9% of cases and inactive in
the remaining cases [24]. ON cells with spontaneous
activity were the only cells investigated and included in
t h ed a t aa n a l y s i st oc h a r a c t e r i z et h ea c t i v i t yo ft h i sO N
cell subgroup more accurately and to consider post drug
changes in their spontaneous activity. Tail flick-related
ON cell burst was calculated as means ± S.E.M. of the
number of spikes in the 10 sec interval starting from the
onset of the increase in cell frequency (which was at
least double its spontaneous activity). Furthermore, the
onset of the ON cell burst was calculated as means ± S.
E.M. (s) of time elapsing between the application of the
noxious radiant heat and the beginning of the tail flick-
related increase in cell frequency. The onset of the OFF
cell pause was calculated as means ± S.E.M of the time
(s) elapsing between the onset of the application of ther-
mal stimulus and the last spike. Finally, the duration of
the cell pause was expressed as means ± S.E.M. of the
time (s) elapsing between the pause onset and the first
spike after the tail flick. For tail flick latency and electro-
physiology data, comparisons were made using 2-way
ANOVA for repeated measures, followed by the New-
man-Keuls post-hoc test. ANOVA followed by the
Tukey post-hoc test were used for immunohistochemis-
try and western blot analysis. P < 0.05 was considered
statistically significant.
Drugs
ONO-DI-004 was kindly provided by ONO Pharmaceu-
tical Co Ltd, Osaka, Japan. (5Z, 11a, 13E, 15S)-11, 15-
dihydroxy-9-oxo-prosta-5, 13-dien1oic acid (Prostaglan-
din E2) was purchased from Tocris Bioscience, Bristol,
UK. (3-{3-[2-(benzyloxy)-5-chlorophenyl]-2-thienyl}phe-
nyl) acetic acid (L-335677) was kindly provided by
Merck Frosst Canada and Co., Quebec, Canada. All
drugs were dissolved in 0.05% DMSO in ACSF.
Results
EP1 expression and localization in the VL PAG
The immunohistochemical approach was used to reveal
EP1 expression and localization within the VL PAG
(Figure 1A). Western blot analysis demonstrated the
presence of EP1 receptor within the VL PAG (Figure
1B). Western blot analysis showed a significant decrease
in EP1 receptor protein levels in the VL PAG of SNI
rats (10004.25 ± 309.42, n = 6, p < 0.05, one-way
ANOVA/Tukey test) compared with the shams (mean
of arbitrary units ± SEM: 21375.5 ± 1041.5, n = 6) 7
days after sciatic nerve surgery (Figure 1B’). Double
labelling revealed that EP1 receptors were mostly
expressed in the VGAT labelled neurons, while few EP1
positive profiles were present in the VGluT1 labelled in
the VL PAG (Figure 1C).
Effect of intra-VL PAG ONO-DI-004 and L335677 on tail
flick latencies
Only rats whose microinjected site was located within
the VL PAG (black circles) were used for data computa-
t i o n( F i g u r e2 A ) .C a n n u l a ew e r ea l s oi n t e n t i o n a l l y
implanted 1 mm outside from VL PAG for microinjec-
tion site controls (white circles).
Tail flicks were elicited every 5 min for 15 min prior
to microinjecting drugs or respective vehicle into the VL
PAG. Data related to pre-treatment intervals were con-
sidered as basal tail flick latencies (5.5 ± 0.6 s). Intra-VL
PAG microinjections of vehicle did not change tail flick
latency (5.2 ± 0.7 s, n = 12) compared with basal values.
Tail flick latency was significantly reduced to 3.7 ± 0.4 s
a n d1 . 8 6±0 . 2s( P < 0.05; F(3-51) = 27.01; n = 14 for
each dose) by intra-VL PAG microinjections of ONO-
DI-004 (0.01 and 0.1 pg) respectively, while the lowest
dose (0.001 pg) did not significantly change (n = 12) the
nocifensive response (Figure 3A). The pronociceptive
effect induced by the highest dose of ONO-DI-004 (0.1
pg) was completely prevented (n = 12) by 10 min pre-
Palazzo et al. Molecular Pain 2011, 7:82
http://www.molecularpain.com/content/7/1/82
Page 5 of 18treatment with L335677 (0.1 pg) (Figure 3A), which was
inactive per se at this dose (n = 13) (Figure 3B). Intra-
PAG administrations of L335677 (1 and 10 pg) signifi-
cantly increased the tail flick latency to 6.7 ± 0.4 and 8
±0 . 3 5s( P < 0.05; F(3-41) = 14.06; n = 12 for both
doses)(Figure 3B). ONO-DI-004 (0.1 pg) was also inten-
tionally microinjected 1 mm from the PAG (n = 7),
where it failed to change tail flick latency (not shown).
Effect of intra-VL PAG ONO-DI-004 and L335677 on tail
flick latencies in sham and SNI rats
In sham and SNI rats, basal tail flick latencies were
similar to pre-treatment intervals (5.3 ± 0.8 s, n = 7 and
3.1 ± 0.6 s, n = 13 respectively). Intra-VL PAG microin-
jection of vehicle did not change tail flick latency in
sham or SNI rats (5.2 ± 0.15 s, n = 12 and 3.2 ± 0.7 s, n
= 12, respectively) compared to basal values. Intra-VL
PAG microinjection of ONO-DI-004 (0.1 pg) signifi-
cantly reduced the tail flick latency to 2.7 ± 0.28 s (P <
0.05; F(1-23) = 55.71; n = 13) and 2 ± 0.2 s (P <0 . 0 5 ;F
(1-24) = 10.9; n = 12) in sham and SNI rats respectively
(Figure 3C). Tail flick latency was significantly increased
to 7.9 ± 0.4 s (P < 0.05; F(1-19) = 42.99; n = 12) and 6.6
±0 . 8s( P < 0.05; F(1-22) = 12.96; n = 12) by intra-VL
PAG microinjections of L-335677 (10 pg) in sham and
SNI rats respectively (Figure 3D).
Effect of intra-VL PAG PGE2 on tail flick latencies
Tail flick latency was significantly reduced to 3.5 ± 0.3 s
and 2.3 ± 0.4 s (P < 0.05; F(4-65) = 14.85; n = 14 for
both doses) by microinjection of PGE2 (0.1 and 1 pg),
respectively. The lowest dose of PGE2 (0.01 pg) only
A
B
1.36 1.20 1.00 mm
-1.80 -2.00 -2.30 mm
Figure 2 Histologically verified microinjection sites for drug or vehicle microinjections in the VL PAG (A) and recording sites for ON
and OFF cells in the RVM (B), in transverse sections simplified by Paxinos and Watson [20]. Vehicle or drug microinjections are depicted
with filled circles (A). The open circles indicate microinjections that were accidentally or intentionally performed outside of VL PAG, the effects of
which (n = 7) were considered in the study for location specificity. Triangles indicate electrode tips in the RVM (B); in particular white triangles
represent ON cells and the black ones represent the OFF cells. Distances (in mm) from the interaural line are indicated.
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post injection (n = 12). The pronociceptive effect
induced by the highest dose of PGE2 (1 pg) was com-
pletely prevented by 10 min pre-treatment with L-
335677 (0.1 pg) (n = 13), which was inactive per se (Fig-
ure 4).
Effect of ONO-DI-004 and L-335677 on the ongoing
activity of RVM ON and OFF cells
The results are based on RVM neurons (one cell
recorded from each animal per treatment) at a depth of
9, 900-10, 955 μm from the surface of the brain. All
recorded neurons identified as ON cells by a burst of
activity immediately prior to tail flick responses were
spontaneously active in 29.2% of cases and inactive in
the remaining ones. Only ON cells showing spontaneous
activity were chosen and included in the analysis of the
data so as to characterize the activity of this ON cell
subgroup more accurately and to consider post-drug
changes in their spontaneous activity. This population of
ON cells had a mean frequency of spontaneous activity
of 7.3 ± 0.5 spikes/s (Figure 5A). ON cells with tail
flick-evoked activity only showed a mean spontaneous
activity of 0.38 ± 0.3 spikes/s and were not included in
data analysis. OFF cells showed a mean spontaneous
a c t i v i t yo f8 . 1±0 . 7s p i k e s / s .M i c r o i n j e c t i o no fv e h i c l e
(0.05% DMSO in ACSF) did not change the sponta-
neous activity of the ON (7.6 ± 0.3 spikes/s, n = 6) (Fig-
ure 5A) or OFF cells (8.1 ± 0.7 spikes/s, n = 6) (Figure
5B). Intra-VL PAG microinjections of ONO-DI-004
(0.01 and 0.1 pg) caused an increase in ON cell activity,
which was significant between 5 and 40 min (14.4 ± 0.8
spikes/s) and 5 and 45 min (19.2 ± 0.7 spikes/s), (P <
0.05, F(3-25) = 40.00; n = 7 for both doses) respectively
(Figure 5A). ONO-DI-004 (0.01 and 0.1 pg) decreased
OFF cell activity and this effect was significant between
5 and 45 min in both cases (5.0 ± 0.4 and 2.2 ± 0.6
spikes/s, respectively) (P < 0.05; F(3-25) = 17.54; n = 7
for both doses) (Figure 5B). The lowest dose of ONO
DI-004 (0.001 pg) did not change the spontaneous
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Figure 3 Tail flick latencies after intra-VL PAG microinjections of vehicle (0.05% DMSO in ACSF), ONO-DI-004 (0.001, 0.01 and 0.1 pg)
alone, or ONO-DI-004 (0.1 pg) in combination with L355677 (0.1 pg) (A) or L335677 (0.1, 1 and 10 pg) (B). Tail flick latencies were also
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(0.1 pg) and D indicates the effects of vehicle or L335677 (10 pg) in sham and SNI rats 7 days after SNI surgery. Each point represents the
mean ± S.E.M of 12-14 rats per group. * indicates a statistically significant difference vs vehicle and° vs ONO-DI-004 (0.1 pg) in A and B.*
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significant.
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Page 7 of 18activity of ON or OFF cells (n = 6 for both cells). The
effects of ONO-DI-004 (0.1 pg) on the ongoing activity
of ON and OFF cells were completely abolished by 10
min pre-treatment with L335677 (0.1 pg, n = 6 for both
cells) (Figure 5A and 5B).
Intra-VL PAG microinjections of L-335677 (1 and 10
pg) caused a decrease in the spontaneous firing activity
of the ON cells, which was already significant after 10
min and lasted for 45 min at both doses (4.6 ± 0.4 and
2.7 ± 0.6 spikes/s, respectively) (P < 0.05; F(3-23) =
22.90; n = 6 for both doses) (Figure 5C). L-335677 (1
and 10 pg) also increased the spontaneous activity of
OFF cells, which was significant between 5 and 45 min
at both doses (11.6 ± 0.6 and 15.4 ± 0.8 spikes/s, respec-
tively) (P < 0.05; F(3-23) = 31.58; n = 6 for both doses)
(Figure 5D). The lowest dose of L335677 (0.1 pg) did
not alter the spontaneous activity of either ON (n = 7)
or OFF (n = 6) cells (Figure 5C and 5D).
Effect of ONO-DI-004 and L-335677 on the ongoing
activity of RVM ON and OFF cells in sham and SNI rats
In sham and SNI rats, the ON cell population showed
a mean frequency of spontaneous activity of 7.2 ± 0.5
and 14.8 ± 1.5 spikes/s, respectively. Therefore the
mean frequency of ON cells in the sham rats did not
differ from that of healthy rats (7.3 ± 0.5 spikes/s),
whereas the mean frequency of ON cell activity in SNI
rats significantly increased compared to both sham and
healthy rats (P < 0.05; F(1-16) = 27.66; n = 6 and P <
0.05; F(1-20) = 25.43; n = 7, respectively). Microinjec-
tion of vehicle (0.05% DMSO in ACSF) did not change
the spontaneous activity of ON cells (7.1 ± 0.8 spikes/
s ,n=6a n d1 5±1 . 3s p i k e s / s ,n=7 )i ns h a mo rS N I
rats, respectively. The intra-VL PAG microinjection of
ONO-DI-004 (0.1 pg) caused an increase in the spon-
taneous firing activity of ON cells, which was signifi-
cant after 5 min and lasted 45 and 60 min (19.2 ± 1.4
spikes/s, P < 0.05; F(1-15) = 52.56; n = 6 and 22.5 ±
2.8 spikes/s, P < 0.05; F(1-19) = 5.52; n = 7) in sham
and SNI rats, respectively. The population of OFF cells
had a mean frequency of spontaneous activity of 8 ±
0.3 and 4.8 ± 0.5 spikes/s in sham and SNI rats,
respectively. The mean frequency of the OFF cells in
t h es h a mr a t st h e r e f o r ed i dn o td i f f e rf r o mt h a to f
healthy rats (8.1 ± 0.7 spikes/s), whereas the mean fre-
quency of OFF cell activity in SNI rats was signifi-
cantly reduced (4.4 ± 0.7 spikes/s), compared to both
sham and healthy rats (P < 0.05; F(1-22) = 6.92; n = 6
and P < 0.05; F(1-22) = 4.66; n = 7, respectively). The
microinjection of vehicle (0.05% DMSO in ACSF) did
Figure 4 Tail flick latencies after intra-VL PAG microinjections of vehicle (0.05% DMSO in ACSF), PGE2 (0.01, 0.1 and 1 pg) or PGE2 (1
pg) in combination with L355677 (0.1 pg). Each point represents the mean ± S.E.M of 12-14 rats per group. * indicates a statistically
significant difference vs vehicle and° versus PGE2 (1 pg). P values < 0.05 were considered statistically significant.
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Page 8 of 18not change the spontaneous activity of OFF cells (8.1 ±
0.9 spikes/s, n = 6; 3.7 ± 0.5 spikes/s, n = 7) in sham
and SNI rats, respectively. Intra-VL PAG microinjec-
tions of ONO-DI-004 (0.1 pg) caused a decrease in the
spontaneous firing activity of OFF cells that was
already significant between 5 min and 50 min and
between 10 and 60 min (3 ± 0.5 spike/s, P < 0.05; F(1-
1 9 )=2 4 . 5 4 ;n=6a n d2 . 2±0 . 4s p i k e s / s ,P<0 . 0 5 ;F
(1-21) = 22.69; n = 7) in sham and SNI rats,
respectively.
Intra-PAG microinjections of L335677 (10 pg)
caused a reduction in ON cell activity that was signifi-
cant between 10 and 45 min and 5 and 60 min (3.9 ±
0.6 spikes/s, P < 0.05; F(1-22) = 10.67; n = 7 and 5.2
± 0.8 spikes/s, P < 0.05; F(1-19) = 39.25; n = 7) in
sham and SNI rats, respectively. Intra-PAG microin-
jections of L335677 (10 pg) caused an increase in OFF
cell activity which was significant between 10 and 50
min and 5 and 60 min (15.5 ± 0.83 spikes/s, P < 0.05;
F(1-20) = 35.73; n = 7; 11.7 ± 1.1 spikes/s, P < 0.05; F
(1-18) = 33.75, n = 7) in sham and SNI rats,
respectively.
Effect of PGE2 on the ongoing activity of RVM ON and
OFF cells
Intra-PAG microinjections of PGE2 (0.01, 0.1 and 1
pg) caused an increase in ON cell activity that was sig-
nificant at 15 min (10.9 ± 0.7 spikes/s, n = 6), between
15 and 40 min (14.7 ± 0.8 spikes/s) and between 15
and 45 min (21.2 ± 1.3 spikes/s), respectively (P <
0.05; F(3-23) = 42.20; n = 7 for the higher doses) (Fig-
ure 6A). Similar treatment reduced OFF cell activity,
with a significant effect at 15 min (6.3 ± 0.4 spikes/s, n
= 6), between 15 and 40 (3.9 ± 0.5 spikes/s) and
between 15 and 45 min (1.4 ± 0.5 spikes/s), respec-
tively (P < 0.05; F(3-23) = 64.66; n = 7 for the higher
d o s e s )( F i g u r e6 B ) .T h ee f f e c t so fP G E 2( 1p g )o n
ongoing ON (n = 6) and OFF cell (n = 7) activity were
completely abolished by 10 min pre-treatment with
L335677 (0.1 pg) (Figure 6A and 6B).
Effect of intra-VL PAG ONO-DI-004 and L-335677 on tail
flick-related ON and OFF cell activity
Microinjections of vehicle did not change the tail flick-
induced ON cell burst (14.08 ± 1.8 spikes/s, n = 6), OFF
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Figure 5 The effects of intra-VL PAG microinjections of vehicle (0.05% DMSO in ACSF), ONO-DI-004 (0.001, 0.01 and 0.1 pg) alone, or
ONO-DI-004 (0.1 pg) in combination with L355677 (0.1 pg) (A and B) or L355677 (0.1, 1 and 10 pg) (C and D), on the spontaneous
firing of RVM ON (A and C) or OFF (B and D) cells. Vehicle or drugs were administered at time 0, whereas L 335677 (0.1 pg) was
administered 10 min beforehand (A and B). Each point represents the mean ± S.E.M of 6-7 neurons. * indicates a statistically significant
difference vs vehicle and° versus ONO-DI-004 (0.1 pg). P values < 0.05 were considered statistically significant.
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Page 9 of 18cell pause (6.95 ± 2.4 s, n = 6) (Figure 7A and 7B) or
the onset of the burst (2.5 ± 1.4 s) and pause (4.1 ± 2.1
s) (Figure 7C and 7D). Intra-VL PAG microinjections of
ONO-DI-004 (0.01 and 0.1 pg) caused an increase in
both the ON cell burst (22 ± 1.3 spikes/s and 27.4 ± 0.9
spikes/s, respectively) (P < 0.05; F(2-20) = 8.81; n = 7
for both doses) and OFF cell pause (12.8 ± 0.4 s and 17
± 1.5 s) (F(2-19) = 25.32; P < 0.05; n = 7 for both doses)
(Figure 7A and 7B for the highest dose only). Further-
more, ONO-DI-004 (0.01 and 0.1 pg) caused a decrease
in the onset of burst to 1.7 ± 0.3 s and 1.3 ± 0.2 s,
respectively (P < 0.05; F(2-19) = 7.98; n = 7 for both
doses) and in the onset of the OFF cell pause to 3.4 ±
0.2 s and 2.6 ± 0.3 s, respectively (P < 0.05; F(2-19) =
Figure 6 Effects of intra-VL PAG microinjections of vehicle (0.05% DMSO in ACSF), PGE2 (0.01, 0.1 and 1 pg) alone, or PGE2 (1 pg) in
combination with L355677 (0.1 pg) on the spontaneous firing of RVM ON (A) or OFF (B) cells. Vehicle or drugs were administered at
time 0, whereas L 335677 (0.1 pg) was administered 10 min beforehand. Each point represents the mean ± S.E.M of 6-7 neurons of different
treated groups of rats. * indicates a statistically significant difference vs vehicle and° versus PGE2 (1 pg). P values < 0.05 were considered
statistically significant.
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Page 10 of 185.83; n = 7 for both doses) (Figure 7C and 7D). The
effects induced by the highest dose of ONO-DI-004 (0.1
pg) were completely prevented by pre-treatment with
the lowest dose of L-335677 (0.1 pg) (n = 6 for both
cells), which was inactive per se (n = 7 for the ON cells
and n = 6 for OFF cells) (Figure 7A and 7B). ONO-DI-
004 (0.001 pg) did not alter tail flick-evoked ON and
OFF cell activity (n = 6 for both doses) (not shown).
Effect of intra-VL PAG ONO-DI-004 and L-335677 on tail
flick-related ON and OFF cell activity in sham and SNI rats
In sham and SNI rats, the population of ON cells had a
tail flick-induced burst of firing of 14.1 ± 1.2 and 22 ±
2.8 spikes/s, respectively (Figure 8A and 8B). Therefore
the mean of the frequency of the ON cell burst in the
sham rats did not differ from that of healthy rats (14.08
±1 . 8s p i k e s / s ,n=6 )w h e r e a st h em e a nf r e q u e n c yo f
the ON cell burst in SNI rats was significantly increased
compared to both sham and healthy rats (P < 0.05; F(1-
14) = 18.77; n = 6 and P < 0.05; F(1-13) = 18.77; n = 7,
respectively). The population of OFF cells showed a
p a u s eo f6 . 3±1 . 3sa n d1 5 . 8±2 . 5si ns h a ma n dS N I
rats, respectively (Figure 8C and 8D). The duration of
the OFF cell pause in the sham rats did not therefore
differ from that of healthy rats (6.65 ± 2.45 s), whereas
the pause of OFF cells in SNI rats significantly increased
compared to both sham and healthy rats (P <0 . 0 5 ;F ( 1 -
16) = 6.26; n = 6 and P < 0.05; F(1-15) = 10.28; n = 7,
respectively). Microinjections of vehicle in sham and
SNI rats did not change the tail flick-induced ON cell
burst (14.0 ± 1.2, n = 6 and 21.8 ± 1.1 spikes/s, n = 6,
respectively) (Figure 8A and 8B) or OFF cell pause (5.9
± 1.4 s, n = 6, and 15.6 ± 2.2 s, n = 6, respectively) (Fig-
ure 8C and 8D). Intra-VL PAG microinjections of
ONO-DI-004 (0.1 pg) caused an increase in both the
ON cell burst (23.1 ± 0.9 spikes/s, P < 0.05; F(1-10) =
36.8; n = 7 and 26 ± 0.37 spikes/s, P < 0.05; F(1-10) =
14.5; n = 6, respectively) and OFF cell pause (18.5 ± 1.8
s, P < 0.05; F(1-11) = 26.70; n = 7 and 22 ± 1.55 s, P <
0.05; F(1-21) = 5.8; n = 7, respectively) (Figure 8A and
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Figure 7 The effects of intra-VL PAG microinjections of vehicle (0.05% DMSO in ACSF), ONO-DI-004 (0.1 pg) alone, or in combination
with L355677 (0.1 pg) on the ON cell tail flick-evoked burst of firing (A) and onset of the burst (C) or OFF cell tail flick-evoked pause
(B) and onset of the pause (D). Each histogram represents the mean ± S.E.M of 6-7 neurons of different treated groups of rats. * indicates
significant differences vs vehicle and° versus ONO-DI-004 (0.1 pg). P values < 0.05 were considered statistically significant.
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Page 11 of 188C) in sham and SNI rats, respectively. Intra-VL PAG
microinjections of ONO-DI-004 (0.1 pg) caused a
decrease in the onset of the ON cell burst (1.3 ± 0.1 s
and 0.22 ± 0.06 s, P < 0.05; F(1-12) = 54.44; n = 6 and
P < 0.05; F(1-12) = 4.41; n = 6) in sham and SNI rats,
respectively. Intra-VL PAG microinjections of ONO-DI-
004 (0.1 pg) also caused a decreasing of the onset of
pause to 2.6 ± 0.3 s and 0.2 ± 0.09 s (P < 0.05; F(1-12)
= 11.68; n = 6 and P < 0.05; F(1-12) = 5.62; n = 6 (Fig-
ure 8D) in sham and SNI rats, respectively.
Intra-VL PAG microinjections of L-335677 (10 pg)
reduced the burst of firing (5.3 ± 1 spike/s and 3.2 ±
1.28 spike/s) (P < 0.05; F(1-10) = 37.85; n = 6 and P <
0.05; F(1-10) = 45.48 n = 6) in sham and SNI rats
respectively (Figure 8B) and increased the onset of ON
cell burst (4 ± 1 s and 0.76 ± 0.04 s) (P < 0.05; F(1-12)
= 114.89; n = 6 and P < 0.05; F(1-12) = 13.61; n = 6) in
sham and SNI rats, respectively. Intra-VL PAG microin-
jections of L-335677 (10 pg) also reduced the OFF cell
pause to 2.9 ± 0.6 s and 4.3 ± 1.3 s (P < 0.05; F(1-12) =
7.4; n = 6 and P < 0.05; F(1-12) = 19.5, n = 6)in sham
and SNI rats, respectively (Figure 8D) as well as increas-
i n gt h eo n s e to fp a u s et o6 . 7±0 . 4sa n d0 . 8 8±0 . 0 8s
(P < 0.05; F(1-12) = 183.2; n = 6 and P < 0.05; F(1-12) =
12.35; n = 6 (Figure 8D) in sham and SNI rats, respec-
tively. Representative ratemeter records showing tail
flick-related activity of ON and OFF cells in sham and
CCI rats before and after ONO-DI-004 (0.1 pg) or
L335677 (10 pg) are shown in Figure 9.
Effect of intra-PAG PGE2 on tail flick-related ON and OFF
cell activity
Intra-VL-PAG microinjections of PGE2 (0.01, 0.1 and
1 pg) caused an increase in the ON cell burst (15.8 ±
1s p i k e / s ,n=6 ,1 9 . 2±1 . 1s p i k e / s ,n=7a n d2 3 . 4±
1.2 spikes/s, n = 7, respectively) (P < 0.05; F(3-25) =
17.36) (Figure 10A for the highest dose only) and OFF
cell pause (6.8 ± 0.8 s, n = 6, 9.9 ± 0.7 s, n = 7 and
11.2 ± 0.4 s, n = 7, respectively) (P < 0.05; F(3-22) =
18.31) (Figure 10B for the highest dose only). PGE2
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Figure 8 The effects of intra-VL PAG microinjections of vehicle (0.05% DMSO in ACSF), ONO-DI-004 (0.1 pg) (A, C) or L355677 (10 pg)
(B, D) on the ON cell tail flick-evoked burst of firing (A and B) and OFF cell tail flick-evoked pause (C and D) in sham and SNI rats 7
days after surgery. Each histogram represents the mean ± S.E.M of 6-7 neurons of different treated groups of rats. * indicates significant
differences vs sham/vehicle and° versus SNI/vehicle. P values < 0.05 were considered statistically significant.
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Page 12 of 18(0.01, 0.1 and 1 pg) also caused a reduction in the
onset of burst to 2.5 ± 0.2 s (n = 6), 1.8 ± 0.3 s (n =
7) and 0.6 ± 0.2 s (n = 7) (P < 0.05; F(3-25) = 18.16),
respectively (Figure 10C for the highest dose only) and
in the OFF cell pause to 4.4 ± 0.2 s (n = 6), 2.8 ± 0.3 s
(n = 7) and 1.5 ± 0.3 s (n = 7), respectively (P < 0.05;
F(3-25) = 17.36) (Figure 10D for the highest dose
only). The effects induced by the highest dose of PGE2
(1 pg) were completely prevented by pre-treatment
with the lowest dose of L-335677 (0.1 pg, n = 6 for the
ON and n = 7 for the OFF cells), which was inactive
p e rs e( n=7f o rt h eO Na n dn=6f o rt h eO F Fc e l l s )
(Figure 10).
Discussion
It is widely agreed that prostaglandins contribute to
nociception facilitation through sensitization of primary
afferent sensory neurons at the site of injury and spinal
circuitry [3,25-27]. The role of supraspinal PGE2 in pain
facilitation remains less explored despite studies which
have demonstrated the presence of PGE2 receptors in
the hypothalamus, hippocampus and PAG [6,7]. A parti-
cularly strong positivity to the polyclonal antibody
against an amino-terminal portion of EP3 receptor and
mRNA have been found within the PAG [7]. The pre-
sence of EP1 receptor, whose role in pain facilitation
has previously been established [12-17], has instead
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Figure 9 Examples of ratemater records which illustrate the effect of intra-VL PAG microinjection of ONO-DI-004 (0.1 pg) or L335677
(10 pg) on either the ongoing or tail flick-related burst of activity of identified RVM ON cells (A, C, E and G) and ongoing or tail flick-
related pause of identified RVM OFF cells (B, D, F and H) in sham (A, B, C and D) and SNI (E, F, G and H) rats. Intra-VL PAG
microinjection of ONO-DI-004 (0.1 pg) increased the ongoing activity and tail flick-related burst of the ON cells in sham and SNI rats (A and E,
respectively). The same treatment reduced the ongoing activity and increased the tail flick-related pause of the OFF cells in sham and SNI rats (B
and F, respectively). Conversely, intra-VL PAG microinjection of L335677 (10 pg) reduced the ongoing activity and tail flick-related burst of the
ON cells both in sham and SNI rats (C and G, respectively). The same treatment increased the ongoing activity and reduced the tail flick-related
pause of the OFF cells in both sham and SNI rats (D and H, respectively). Scales bars indicate 5 min for ratemater records, while small full arrows
indicate the noxious stimulation. At the right a time expanded scale illustrates pause duration changes (scale bar = 5 sec). The grey arrows show
the noxious stimuli application and the black one the tail flick reflex.
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Page 13 of 18never been ascertained within the PAG. Previous evi-
dence has suggested a facilitatory role of PGE2 within
the PAG on pain transmission [10,11]. One of our pre-
vious studies has shown that VL PAG EP1 receptor
blockade inhibited pain responses or misoprostol-
induced effect [12]. In the present study, the expression
of EP1 receptor in the VL PAG was ascertained by wes-
tern blot and immunohistochemistry. Our results
demonstrate that EP1 receptors were widely expressed
within the VL PAG and co-localize with the vesicular
GABA transporter (VGAT) positive profile. The
GABAergic neural population constitutes ~ 50% of total
neural elements (the majority are active tonic interneur-
ons) of the PAG controlling its intrinsic activity which
affects the antinociceptive descending circuitry function
[28,29]. EP1 receptor is associated with Ca
2+ mobiliza-
tion and neurotransmitter release [3,18]. Consistent with
a previous finding in the striatum suggesting that EP1
receptor can be expressed on either the presynaptic or
postsynaptic membrane [30], EP1 receptor stimulation
in our study could be associated with GABA release. An
increase in GABA release within the VL PAG has
already been shown for misoprostol, a non-specific pros-
taglandin analogue [12], which activates all EP receptors.
In another study, sulprostone, an EP3 receptor selective
agonist, and PGE2 inhibited miniature excitatory postsy-
naptic currents (mEPSCs), with no action on inhibitory
postsynaptic currents (mIPSCs), demonstrating the role
of EP3 receptor in decreasing glutamate release from
presynaptic sites [31]. Changes in excitatory and/or inhi-
bitory neurotransmitters have a relevant meaning within
the PAG, since its stimulation and/or depression is con-
sistent with pain inhibition and/or facilitation. More-
over, despite the potential for persistent exposure to
prostaglandins at t h ep e r i p h e r a ls i t eo fi n j u r yo rw i t h i n
the CNS, few studies have been performed to assess the
effect of prostaglandin receptor expression and mediated
responses in chronic pain conditions [32]. In neuro-
pathic pain conditions induced by the SNI of the sciatic
nerve, a reduced expression of EP1 receptor was
observed within the VL PAG 7 days after the surgery. A
significant decrease of EP receptor in chronic pain
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Figure 10 The effects of intra-VL PAG microinjections of vehicle (0.05% DMSO in ACSF), L335677 (10 pg), PGE2 (1 pg) alone, or PGE2
(1 pg) in combination with L355677 (0.1 pg) on the ON cell tail flick-evoked burst of firing (A) and onset of the burst (C), or OFF cell
tail flick-evoked pause (B) and onset of the pause (D). Each histogram represents the mean ± S.E.M of 6-7 neurons of different treated
groups of rats. * indicates significant differences vs vehicle and° versus PGE2 (1 pg). P values < 0.05 were considered statistically significant.
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Page 14 of 18conditions has already been observed in the DRG, spinal
cord dorsal horn and sensory neurons [32,33]. EP recep-
tor downregulation appeared to be PGE2-mediated,
since it was abolished by intrathecal administration of
ketoralac, an inhibitor of the COXs, which proved to be
overexpressed in inflammatory pain conditions [34,35].
Selective stimulation of EP1 receptor by intra-VL PAG
microinjection of ONO-DI-004, a selective EP1 receptor
agonist, as well as the stimulation of all EP receptors by
PGE2, decreased the latency of the thermoceptive reac-
tion. The facilitation of nociceptive responses by intra-
VL PAG PGE2 is consistent with previous studies
demonstrating that the direct application of PGE2
within the VL PAG was able to facilitate nociceptive
responses in lightly anaesthetized rats [10,11]. Here, as
well as confirming this previous evidence using a differ-
ent themoceptive test; the tail flick, we also show that
selective EP1 stimulation by ONO-DI-004 is able to
induce the facilitation of nociception. Moreover, this
study shows that L335677, a selective EP1 receptor
antagonist, which was unable to alter the thermal
threshold at a low dose, completely prevented the effects
of intra-VL PAG microinjections of ONO-DI-004 and
PGE2. The fact that EP1 selective antagonist completely
prevents the PGE2-induced effect suggests that the
PGE2-induced hyperalgesic effect requires the involve-
ment of EP1 receptor. This dependence of large spec-
trum EP receptor agonist on each EP receptor has
already been emerged with misoprostol, a synthetic
PGE2 analogue, whose effect has been shown to require
EP1, EP2, EP3 and EP4 receptor stimulation [12].
Moreover EP1 receptor blockade by L335677 (at
higher doses than those used for antagonizing ONO-DI-
004 and PGE2 effects) increased per se the latency of
the thermoceptive reaction. Since EP1 receptor blockade
by L335677 produced antinociception, it appears that
this receptor is under tonic activation in facilitating the
nociceptive response within the VL PAG. Therefore
taken together, this study and previous ones [10,11] sug-
gest that apart from performing an inhibitory role, VL
PAG also mediates facilitatory pain control. A tonic
facilitatory role of EP1, EP2, EP3 and EP4 receptors,
whose blockade determined analgesia, has already been
found in formalin-induced persistent pain conditions
[12]. However, it has scarcely been investigated in neu-
ropathic pain conditions [17]. ONO-DI-004 and
L335667 were both effective in changing the nociceptive
reaction in a facilitatory and inhibitory manner, respec-
tively in neuropathic pain conditions in this study. In
this study it is significant to observe that neuropathic
pain, which leads to almost a 50% reduction in EP1
receptor expression, did not alter the effect of EP1
ligands in changing pain response in the VL PAG
according to a previous study in the sensory neurons
and spinal cord [32]. Possible explanations for the main-
tained pain-related activity of EP1 receptor stimulation/
blockade in the face of its downregulation may be due
to: i) the presence of spare receptors whose reduction in
expression does not affect their related response; ii) loss
of receptor on a certain cell population not involved in
controlling pain at this level or iii) a minimal threshold
concentration of EP1 receptor-associated transduction
enzyme despite the elevated number of EP1 receptors in
the VL PAG in normal conditions. Further studies are
necessary to clarify this issue.
Prostaglandin-induced pain facilitation involves the
recruitment of the pain-responding neuron population in
the RVM [11]. The PAG modulatory effect on pain con-
trol involves RVM neuron activity. In this study, intra-VL
PAG ONO-DI-004 modified both spontaneous and tail
flick-related activities of ON and OFF cells. In particular,
it increased the spontaneous activity of the “pronocicep-
tive” ON cells and reduced the spontaneous activity of
the “antinociceptive” OFF cells, as a facilitating nocicep-
tion drug is expected to do [11]. ONO-DI-004 also
decreased the onset of the ON cell burst and OFF cell
pause, together with an increase in the burst frequency
and pause duration; all of which are effects that are criti-
cal for pain facilitation. The same effects on RVM cell
activity were produced by PGE2, which stimulates all
EP1-4 receptors. In our study we also observed that the
effect of ONO-DI-004, and more intriguingly that of
PGE2, were completely prevented by L335677, a selective
EP1 receptor antagonist. PGE2 has a high affinity for all
EP receptors [36], thus the complete blockade of PGE2-
induced behavioural and electrophysiological effects by
L335677 would suggest that: i) the participation of all EP
receptors is necessary for the nociceptive facilitation as in
“an in series” circuitry; ii) receptors other than EP1 and
EP3 are not present within the VL PAG, a hypothesis
which is however contradicted by a previous study [12]
and iii) EP2, EP3 and EP4 receptors are not involved in
controlling nociceptive and ON and OFF cell activity
responses. The most likely possibility in our opinion
w o u l ds e e mt ob et h a tt h ei n v o l v e m e n to fa l lE Pr e c e p -
tors is required for the nociceptive facilitation of PGE2,
since apart from preventing misoprostol-induced hyper-
algesia [12] within the DL PAG, individual EP1, EP2, EP3
and EP4 receptor antagonists also proved to be analgesic
in formalin-induced persistent pain [12]. We cannot
exclude, however, that in the VL PAG sub-region, in
healthy animals and in a different rodent species (rats
versus mice) EP2, EP3 and EP4 are not involved in con-
trolling nociception or RVM cell activity, or that the
higher doses used in one of our previous studies [12]
have involved other receptor subtypes. Further studies
with selective EP2, EP3 and EP4 receptor antagonists or
knock out mice are therefore necessary in order to clarify
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Page 15 of 18this issue. However, what seems important in the current
study is that intra-VL PAG microinjection of L335677
inhibits nociception and reduces the spontaneous and
tail flick-related activity of the ON cells in the RVM.
Moreover, L335677 produced an increase in spontaneous
OFF cell activity as well as an increase in the onset of the
OFF cell pause, together with a decrease in the duration
of the pause. Such effects are consistent with behavioural
analgesia and could be important in experimental pain
models such as inflammatory and neuropathic pain.
Our data shows that 7 days after sciatic nerve insult,
RVM cell activity changes in such a way that the
ongoing ON cell activity increased and that of the OFF
cell decreased. Apart from the ongoing activity, the tail
flick stimulated activity also changed in nerve injured
rats. The burst and onset of the burst of the ON cells
increased and decreased, respectively. Consistently, the
pause and onset of the pause of the OFF cell increased
and decreased respectively in neuropathic rats. Thus it
appears that ON and OFF cell activity in the RVM
undergoes functional phenotypic change after SNI
which leads to ON cell hyperactivity and OFF cell
hypoactivity after neuropathic pain induction. Changes
in the pain descending system contributing to chronic
pain symptoms have been reported [37-40]. In particular
an increased activity of ON cell, together with a depres-
sion of OFF cell activity 1 week after SNI have already
been observed within the RVM [41]. Moreover in this
study, as well as decreasing tail flick latency EP1 recep-
tor stimulation was still able to increase and decrease
ON and OFF cell activities as far as the ongoing or the
flick related activity was concerned. More interestingly,
EP1 receptor blockade by L335677, at the same doses
used in healthy animals, increased tail flick latency and
modified the ongoing and tail flick-evoked activity of
ON and OFF cells, consistently with behavioural analge-
sia. Evidence of effectiveness of a selective EP1 receptor
antagonist on hyperalgesia and allodynia in neuropathic
pain state has already been reported [17,42] after sys-
temic administration.
The first part of the study showed the location of EP1
receptor within VGAT positive cell population within
the VL PAG. EP1 receptor stimulation is associated with
changes in calcium concentration and neurotransmitter
release, which would increase GABAergic tone, thereby
inhibiting the antinociceptive descending pathway. This
would generate behavioural pain facilitation through a
GABAergic interneuron activation of RVM ON cells
and a direct inhibition of RVM OFF cells. Conversely,
the tonically active EP1 receptor blockade would gener-
ate the opposite effect and dis-inhibit the PAG descend-
ing pathway, generating antinociception. EP1 receptor
blockade-induced nociception inhibition at PAG level is
associated with ON cell inhibition and OFF cell
activation (and with the opposite electrophysiological
effect in the case of ONO-DI-004 and PGE2). As far as
the RVM ON and OFF cell involvement on intra-VL
PAG ONO-DI-004, PGE2 and L335677 effect is con-
cerned, the current study only shows correlative and
synchronous changes in ON and OFF cell activity and
thermonociceptive responses. Nevertheless there is
increasing evidence to suggest that the switching off of
the ON cells, which are the nociceptive facilitating neu-
rons to the dorsal horns [43,44] and activation of OFF
cell activity are critical events in the production of anti-
nociception. Another issue of the study regards the
doses of ONO-DI-004, L335677 and PGE2 chosen. As
far as the PGE2 is concerned, the doses used in the cur-
rent study match those used in another study using the
same intra-PAG administration route [11]. ONO-DI-004
and L335667 have never been microinjected within the
PAG. Therefore given that most synthetic EP receptor
compounds mantain selectivity for their target receptor
subtype in low nM, or an even lower range, we microin-
jected doses (few pgs in 0.2 μl) which are within or even
under the limit of selectivity. Moreover, we tested for
both L335677 (0.1 pg) and ONO-DI-004 (0.001 pg) ten-
fold lower doses, which proved to be devoid of activity.
Conclusions
In conclusion, this study suggests that the presence
within the VL PAG of EP1 receptor, whose activation
with a selective EP1 receptor agonist ONO-DI-004 or
PGE2, which stimulates all EP receptors, facilitates noci-
ceptive responses and modifies the activity of RVM ON
and OFF cells, consistently with pain facilitation, may be
a suitable target for inducing antinociception. Indeed, its
blockade by L335677, a selective EP1 receptor antago-
nist, leads to pain inhibition through the depression and
enhancement of ON and OFF cell activity, respectively,
in normal and neuropathic pain conditions. Although
VL PAG EP1 receptor shows approximately 50% loss of
expression in neuropathic conditions, EP1 receptor
blockade still alleviates pain response. The mechanism
by which EP1 ligands maintain their efficacy in the pre-
sence of EP1 downregulation in neuropathic pain war-
rants further study.
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